Provident Living Financial Services Inc. Takes $1 Million Position in Johnson & Johnson $JNJ

Key Points

• Provident Living Financial Services bought 4,838 shares of Johnson & Johnson in Q4 valued at approximately $1,001,000, representing 1.0% of the fund’s holdings and its 22nd-largest position.
• Wall Street sentiment is broadly positive—most analysts rate JNJ a Buy/Moderate Buy with an average price target around $238, and Morgan Stanley raised its target to $267—supporting upside expectations.
• Institutional ownership stands at 69.55% with several funds boosting their stakes, while insiders sold about 30,142 shares (≈$7.36M) over the past 90 days.

Provident Living Financial Services Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 4,838 shares of the company's stock, valued at approximately $1,001,000. Johnson & Johnson accounts for 1.0% of Provident Living Financial Services Inc.'s holdings, making the stock its 22nd largest position.

Several other hedge funds have also recently bought and sold shares of the company. Hartford Financial Management Inc. lifted its position in Johnson & Johnson by 1.8% in the 4th quarter. Hartford Financial Management Inc. now owns 10,483 shares of the company's stock valued at $2,169,000 after purchasing an additional 187 shares during the last quarter. Prime Capital Investment Advisors LLC lifted its position in Johnson & Johnson by 2.2% in the 4th quarter. Prime Capital Investment Advisors LLC now owns 86,807 shares of the company's stock valued at $17,965,000 after purchasing an additional 1,851 shares during the last quarter. Stone House Investment Management LLC lifted its position in Johnson & Johnson by 58.9% in the 4th quarter. Stone House Investment Management LLC now owns 197 shares of the company's stock valued at $41,000 after purchasing an additional 73 shares during the last quarter. Woodmont Investment Counsel LLC lifted its position in Johnson & Johnson by 1.2% in the 4th quarter. Woodmont Investment Counsel LLC now owns 89,859 shares of the company's stock valued at $18,596,000 after purchasing an additional 1,105 shares during the last quarter. Finally, BIP Wealth LLC lifted its position in Johnson & Johnson by 35.2% in the 4th quarter. BIP Wealth LLC now owns 14,972 shares of the company's stock valued at $3,099,000 after purchasing an additional 3,899 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Morgan Stanley raised its price target to $267 and kept an "Overweight" rating, signaling roughly double-digit upside versus current levels and supporting buy-side interest. Read More.
• Positive Sentiment: Other broker notes (Guggenheim, Citi, and various upgrades) have recently pushed bullish research and helped intraday rallies. Read More.
• Positive Sentiment: Commercial/MedTech catalyst — J&J launched the VARIPULSE Pro pulsed field ablation system in Europe after CE mark approval, adding potential device revenue upside and real‑world evidence generation. Read More.
• Positive Sentiment: Dividend profile remains a tailwind for income investors — long streak of annual increases (>60 years) supports total‑return buyers. Read More.
• Neutral Sentiment: Fair‑value/target updates are moving modestly (consensus fair value around ~$241.7) — analysts are lifting some targets while flagging execution as the next focus, keeping valuation views mixed. Read More.
• Neutral Sentiment: Market is positioning for Q1 earnings — multiple previews and Wall Street estimate rundowns are circulating; that typically increases volatility into the print. Read More.
• Negative Sentiment: Some analysts and commentators are cautioning that this is “time to sell the rally” into Q1, arguing upside expectations may be priced in and that near‑term catalysts could disappoint. Read More.
• Negative Sentiment: Ongoing risks — litigation exposure, biosimilar competition and pricing pressure are repeatedly flagged as potential earnings/headwind items that could cap upside. Read More.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JNJ shares. Weiss Ratings reiterated a "buy (b)" rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Guggenheim boosted their price target on shares of Johnson & Johnson from $240.00 to $244.00 and gave the stock a "buy" rating in a research report on Tuesday, April 7th. TD Cowen began coverage on shares of Johnson & Johnson in a research report on Wednesday. They set a "buy" rating and a $250.00 price target on the stock. Citigroup boosted their price target on shares of Johnson & Johnson from $274.00 to $285.00 and gave the stock a "buy" rating in a research report on Tuesday, April 7th. Finally, Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a "hold" rating in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $238.17.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $238.34 on Friday. The firm's 50 day moving average is $241.29 and its 200-day moving average is $215.26. The stock has a market capitalization of $574.06 billion, a P/E ratio of 21.57, a P/E/G ratio of 2.36 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 12-month low of $146.12 and a 12-month high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company's stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 30,142 shares of company stock worth $7,360,528 in the last ninety days. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.